Tag Archives: M&A

From Cyprus to Cambridge: The Rise of Anna Protopapas, Millennium Takeda's New President

Takeda’s Oncology Taskmaster Millennium Takeda’s new president, Anna Protopapas, explains to Pharm exec’s William Looney the life choices that brought her from Cyprus to Cambridge—and a lead position in the hotly contested search to make cancer a treatable disease. PE: The ascent to the “c suite” is not exclusively the result of hard work. Culture, […]
Posted in Global, Strategy | Also tagged , , , | Leave a comment

GSK: A Rebuffed Suitor for the Moment

By Patricia Van Arnum. Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share.  Although rejecting GSK’s initial bid, HGS kept the door open for other suitors, including again GSK. HGS has authorized its board of directors to explore strategic alternatives for the company, including a […]
Posted in Deals, Guest Blog | Also tagged , , , | 1 Comment

Uncertain Outlook for Pharma and Biotech Deals Following 'Turbulent' 2011

Peter Young, President and Managing Director of international investment bank Young & Partners, looks at what lies ahead for pharma and biotech following a turbulent 2011. The business outlook for pharma companies for the rest of 2012 and beyond is mixed, as pharma companies struggle to realign themselves to a new business model that will […]
Posted in Global, Guest Blog, leadership, Strategy | Also tagged , , , , | Leave a comment

Putting the M Back in M&A

Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large. Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from […]
Posted in Agency Insight, Biotech, Deals, FDA | Also tagged , , | Leave a comment

With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation

If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon. The deal is expected to skyrocket Teva’s brand drug portfolio to $7 billion in annual sales, making Teva “not only the world’s largest generics company, but also one of the […]
Posted in Deals, Strategy | Also tagged , , , | 3 Comments
  • Categories

  • Meta